Drug-coated balloons for the prevention of vascular restenosis

Circulation

Volumn 121, Issue 24, 2010, Pages 2672-2680

  Gray, William A ^a   Granada, Juan F ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

balloon; balloon angioplasty; coronary disease; paclitaxel; peripheral vascular disease; restenosis

Indexed keywords

IOPROMIDE; PACLITAXEL; POLYMER;

ANGIOCARDIOGRAPHY; BALLOON; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RESEARCH; HUMAN; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; HUMANS; PACLITAXEL; TREATMENT OUTCOME;

EID: 77954077036     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.936922     Document Type: Review

References (55)

1. Nikol S, Huehns TY, Hofling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis. 1996;123:17-31.
2. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. 1995;76:996-1002.
3. Tenaglia AN, Fortin DF, Califf RM, Frid DJ, Nelson CL, Gardner L, Miller M, Navetta FI, Smith JE, Tcheng JE, Stack RS. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J Am Coll Cardiol. 1994;24:1004-1011.
4. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
5. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and the hypercho-lesterolemic Yucatan micropig. Circulation. 1994;89:2816-2821.
6. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res. 1994;75:650-658.
7. Gertz SD, Gimple LW, Banai S, Ragosta M, Powers ER, Roberts WC, Perez LS, Sarembock IJ. Geometric remodeling is not the principal pathogenetic process in restenosis after balloon angioplasty: evidence from correlative angiographic-histomorphometric studies of atherosclerotic arteries in rabbits. Circulation. 1994;90:3001-3008.
8. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyn-drickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med. 1994 25;331:489-495.
9. Brower V. Stents and biology combination for restenosis. Nat Biotechnol. 1996;14:422.
10. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980. (Pubitemid 34693829)
11. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-3206.
12. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:625-628.
13. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-1510.
14. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810-814.
15. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-2124.
16. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699.
17. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horseradish per-oxidase: a new catheter approach. Atherosclerosis. 1987 65:215-225.
18. Hong MK, Wong SC, Farb A, Mehlman MD, Virmani R, Barry JJ, Leon MB. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coron Artery Dis. 1993;4:1023-1027.
19. Rasheed Q, Cacchione JG, Berry J, Richards F, Bryant L, Strony J, Enger C, Hodgson JM. Local intramural drug delivery using an infusion balloon following angioplasty in normal and atherosclerotic vessels. Cathet Cardiovasc Diagn. 1994;33:240-245.
20. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J. 1991;122:1136-1140.
21. Camenzind E, Bakker WH, Reijs A, van Geijlswijk IM, Boersma E, Kutryk MJ, Krenning EP, Roelandt JR, Serruys PW. Site-specific intracoronary heparin delivery in humans after balloon angioplasty: a radioisotopic assessment of regional pharmacokinetics. Circulation. 1997;96:154-165.
22. Wilensky RL, March KL, Gradus-Pizlo I, Schauwecker D, Michaels MB, Robinson J, Carlson K, Hathaway DR. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am Heart J. 1995;129:852-859.
23. Marks AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med. 2003;349:1307-1309.
24. Heller PF. Paclitaxel and arterial smooth muscle cell proliferation. Circulation. 1998 28;97:1651. Letter.
25. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645. (Pubitemid 27329445)
26. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Beregi JP. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338.
27. Bittl JA. Catheter interventions for hemodialysis fistulas and grafts. J Am Coll Cardiol Cardiovasc Interv. 2010;3:1-11.
28. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415-1420.
29. Dommke C, Haase KK, Suselbeck T, Streitner I, Haghi D, Metz J, Borggrefe M, Herdeg C. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb Haemost. 2007;98:674-680.
30. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, Heinle H, Karsch KR. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969-1976.
31. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Kuttner A, Schroder S, Haase KK, Karsch KR. Visualization and comparison of drug effects after local paclitaxel delivery with different catheter types. Basic Res Cardiol. 1999;94:454-463.
32. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci. 2001;90:1324-1335.
33. Wiskirchen J, Schober W, Schart N, Kehlbach R, Wersebe A, Tepe G, Claussen CD, Duda SH. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004;39:565-571.
34. Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart. 2007;93:922-927.
35. Buerke M, Guckenbiehl M, Schwertz H, Buerke U, Hilker M, Platsch H, Richert J, Bomm S, Zimmerman GA, Lindemann S, Mueller-Werdan U, Werdan K, Darius H, Weyrich AS. Intramural delivery of sirolimus prevents vascular remodeling following balloon injury. Biochim Biophys Acta. 2007;1774:5-15.
36. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA. 2004;101:9463-9467.
37. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol. 2008;28:820-826.
38. Zou W, Cao G, Xi Y, Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv. 2009;16:15-23.
39. Chen YW, Smith ML, Sheets M, Ballaron S, Trevillyan JM, Burke SE, Rosenberg T, Henry C, Wagner R, Bauch J, Marsh K, Fey TA, Hsieh G, Gauvin D, Mollison KW, Carter GW, Djuric SW. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosup-pression. J Cardiovasc Pharmacol. 2007;49:228-235.
40. Cremers B, Speck U, Kaufels N, Mahnkopf D, Kuhler M, Bohm M, Scheller B. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101:201-206.
41. Herdeg C, Goehring-Frischholz K, Zuern C, Geisler T, Hartmann U, Hoevelborn T, Haase KK, Gawaz M. Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis. Thromb Res. 2008;123:236-243.
42. Oberhoff M, Herdeg C, Al Ghobainy R, Cetin S, Kuttner A, Horch B, Baumbach A, Karsch KR. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv. 2001;53:562-568.
43. Scheller B, Kuhler M, Cremers B, Mahnkopf D, Bohm M, Boxberger M. Short-and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. Clin Res Cardiol. 2008;97:118-123.
44. Thim T, Milewski K, Tellez A, Cheng Y, Wallace-Bradley D, Aboodi MS, Kaluza GL, Schwartz RS, Granada JF. Biological effect on coronary restenosis of bare metal stents crimped on paclitaxel coated balloons: preliminary animal data in the porcine overstretch model. Am J Cardiol. 2009;104:177-D. Abstract.
45. Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009;98:325-330.
46. Albrecht T, Speck U, Baier C, Wolf KJ, Bohm M, Scheller B. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol. 2007;42:579-585.
47. Milewski K, Tellez A, Conditt G, Yi G, Aboodi MS, Thim T, Stenoien M, McGregor JC, Granada JF, Kaluza GL. Pilot study of paclitaxel eluting balloon (Cotavance Technology) followed by bare metal stent implantation: effect on neointimal formation in the iliofemoral arterial territory of normal swine. Am J Cardiol. 2009;104:181-D. Abstract.
48. Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Bohm M, Scheller B. Inhibition of coronary neointimal hyperplasia in swine using a novel zotarolimus-eluting balloon catheter. Eur Heart J. 2009;30:532. Abstract.
49. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008;97:773-781.
50. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119: 2986-2994.
51. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J, Minar E. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-2749.
52. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
53. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Beregi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106:1505-1509.
54. Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315.
55. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in fem-oropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-13565.